Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maruan Hijazi has a total of 84 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Neuro-mimetic reprogramming and epigenetic unlocking drive lung cancer stem cell adaptation to the brain microenvironment

    by Elisa Arias-Romero, Ángeles Fernández-Fondevila, Alejandra Macías-Cerro, Beatriz Fernández-Roldán, Pilar Cerveró-García, Vinothini Rajeeve, Rafael Coveñas, Arantxa Tabernero, Pedro R. Cutillas, Maruan Hijazi

    Brain metastasis represents a lethal complication of non-small cell lung cancer, driven by the ability of disseminated tumor cells to colonize the central nervous system microenvironment. Although cancer stem cells (CSCs) are recognized as key drivers of metastatic initiation, whether their contact with the brain parenchyma induces terminal differentiation or adaptive plasticity remains controversial. Here, using an in vivo model of lung-derived CSCs injected intracranially, combined with quantitative total proteomics and phosphoproteomics, we demonstrate that contact with the brain niche triggers a neuro-mimetic reprogramming rather than terminal differentiation. Lung CSCs desensitize their systemic metastatic program while epigenetically unlocking neural stem cell networks, characterized by the upregulation of Ngfr, Fabp7, Pbx3, Vgf, and S100b, concurrent with the downregulation of the DNA methyltransferase Dnmt3a and the cytosolic exclusion of Id1. Phosphoproteomic profiling revealed post-translational adaptations, highlighted by hyperphosphorylation of Nestin at S957 and S963. Furthermore, kinase substrate enrichment analysis uncovered high activity of Prkcq (PKCθ) and Map3k7 (TAK1), shifting the cellular state toward structural remodelling and microenvironmental stress tolerance. Functional validation assays using selective inhibitors confirmed that these kinase networks represent adaptive liabilities within tissue constraints rather than basic in vitro survival requirements. Together, our findings demonstrate that lung CSCs exploit a phenotypic plasticity to adapt to the brain niche, acquiring a neural-glial disguise that supports vascular co-option, immune evasion, and metastatic colonization.

  • Open Access

    Editorial for the Special Issue “Current Research on Cancer Biology and Therapeutics: Fourth Edition”

    by Maruan Hijazi, Rafael Coveñas

    The fourth edition of this Special Issue, entitled Current Research on Cancer Biology and Therapeutics, includes twelve papers (nine articles and three reviews)

  • Open Access

    Targeting Kinase Signaling in Glioblastoma: Structural Optimization, Blood–Brain Barrier Dynamics and Combinatorial Translational Strategies

    by Diana Juanes-Gusano, Beatriz Fernández-Roldán, Rafael Coveñas, Maruan Hijazi

    Small-molecule kinase inhibitors offer a compelling therapeutic strategy for glioblastoma, yet their clinical efficacy remains severely limited by blood–brain barrier penetration and active efflux transporter extrusion. This review evaluates current medicinal chemistry approaches and translational paradigms to overcome these drug delivery and biological constraints. A critical analysis of the literature reveals that direct structural optimization faces a multidimensional balancing act; next-generation design must prioritize macrocyclization, structural rigidification, and bioisosteric capping to lower polar surface area and evade P-glycoprotein and BCRP efflux. Furthermore, carrier-mediated prodrugs targeting the LAT1 transporter provide a viable rescue strategy for highly potent scaffolds. Reviewing recent clinical failures, such as paxalisib and osimertinib, underscores that single-node monotherapies fail due to compensatory pathway hyperactivation and clonal heterogeneity, whereas multi-targeted agents or rational dual-node combinations prevent rapid tumor adaptation. Additionally, combining kinase inhibitors with DNA damage repair inhibitors, immune checkpoint modulation, or MR-guided focused ultrasound could provide powerful synergistic networks. Finally, bridging the translational gap requires complementing conventional serum-cultured cell lines with patient-derived glioma stem cells and orthotopic xenografts to better recapitulate the cellular architecture of the disease. Ultimately, overcoming the therapeutic challenges in glioblastoma demands a fundamental pivot toward rigorous neuro-pharmacological design and multi-lineage network oncology.


  • Open Access

    The Src inhibitor peptide TAT-Cx43266-283 improves survival in an intracranial murine model of lung cancer brain metastasis

    by Pilar Cerveró-García, Enrique Jiménez-Madrona, Andrea Álvarez-Vázquez, Raquel Flores-Hernández, Laura García-Vicente, Laura García-Guerrero, Juan José Alonso-Amador, Raúl González-Sánchez, Claudia Ollauri-Ibáñez, María Paniagua-Sancho, et al.

    Background: TAT-Cx43266-283 is a novel Src inhibitor, which has shown noteworthy antitumor effects in preclinical models of glioblastoma. Because Src plays a pivotal role in several tumor types, including lung cancer brain metastasis derived from non-small cell lung cancer (NSCLC) cells, we investigated the effect of TAT-Cx43266-283 in NSCLC-derived brain metastasis, a disease of unmet clinical need. Methods: The effect of TAT-Cx43266-283 was studied in Lewis Lung Carcinoma (LLC), LSZ4, A549, and H441 NSCLC cells. The non-adherent stem-like LLC cells (LLC-CSCs) were intracranially implanted in immunocompetent mice to study the effect of TAT-Cx43266-283 in vivo. Phosphoproteomic analysis was employed to identify signaling pathways affected by TAT-Cx43266-283, and the most prominent were validated by Western blot and immunohistochemistry. Datasets of human NSCLC adenocarcinoma were also analyzed. Results: TAT-Cx43266-283 significantly reduced LLC-CSCs viability and increased the survival of mice bearing brain tumors derived from these cells. Phosphoproteomic analysis identified MEK and ERK as key effectors of this treatment. TAT-Cx43266-283 induced apoptosis, impaired cytoskeletal dynamics and disrupted tumor vascularization. Patient datasets revealed that the targets of TAT-Cx43266-283 were significantly enriched in KRAS-altered lung tumors. Functional validation in several human and mouse KRAS-mutated non-adherent NSCLC cells confirmed that TAT-Cx43266-283 reduced their growth and invasiveness. Conclusions: Our results suggest that TAT-Cx43266-283 is a promising antitumor drug for lung cancer brain metastasis, as judged by the dual inhibition of Src and the MEK-ERK pathway in KRAS-mutated NSCLC. This study opens new avenues for exploring TAT-Cx43266-283 in other tumor types driven by these molecular alterations.


  • Open Access

    eEF2K Activity Determines Synergy to Cotreatment of Cancer Cells With PI3K and MEK Inhibitors

    by Maruan Hijazi, Pedro Casado, Nosheen Akhtar, Saul Alvarez-Teijeiro, Vinothini Rajeeve, Pedro R. Cutillas


  • Targeting the lysine-specific demethylase 1 rewires kinase networks and primes leukemia cells for kinase inhibitor treatment

    by Federico Pedicona, Pedro Casado, Maruan Hijazi, John G. Gribben, Kevin Rouault-Pierre, Pedro R. Cutillas

    Most tumor types either fail to respond or become resistant to kinase inhibitors, often because of compensatory prosurvival pathways in the cancer cell’s broader signaling circuitry. Here, we found that intrinsic resistance to kinase inhibitors in cultured primary acute myeloid leukemia (AML) cells may be overcome by reshaping kinase networks into topologies that confer drug sensitivity. We identified several antagonists of chromatin-modifying enzymes that sensitized AML cell lines to kinase inhibitors. Of these, we confirmed that inhibitors of the lysine-specific demethylase (LSD1; also known as KDM1A) rewired kinase signaling in AML cells in a way that increased the activity of the kinase MEK and that broadly suppressed the activity of other kinases and feedback loops. As a result, AML cell lines and about half of primary human AML samples were primed for sensitivity to the MEK inhibitor trametinib. Primary human cells with KRAS mutations and those with high MEK pathway activity were the best responders to sequential treatment with LSD1 inhibitors then trametinib, whereas those with NRAS mutations and high mTOR activity were poor responders. Overall, our study reveals the MEK pathway as a mechanism of resistance to LSD1 inhibitors in AML and shows a way to modulate kinase network circuitry to potentially overcome therapeutic resistance to kinase inhibitors.


  • Open Access

    Drug ranking using machine learning systematically predicts the efficacy of anti-cancer drugs

    by Henry Gerdes, Pedro Casado, Arran Dokal, Maruan Hijazi, Nosheen Akhtar, Ruth Osuntola, Vinothini Rajeeve, Jude Fitzgibbon, Jon Travers, David Britton, et al.

    Artificial intelligence and machine learning (ML) promise to transform cancer therapies by accurately predicting the most appropriate therapies to treat individual patients. Here, we present an approach, named Drug Ranking Using ML (DRUML), which uses omics data to produce ordered lists of >400 drugs based on their anti-proliferative efficacy in cancer cells. To reduce noise and increase predictive robustness, instead of individual features, DRUML uses internally normalized distance metrics of drug response as features for ML model generation. DRUML is trained using in-house proteomics and phosphoproteomics data derived from 48 cell lines, and it is verified with data comprised of 53 cellular models from 12 independent laboratories. We show that DRUML predicts drug responses in independent verification datasets with low error (mean squared error < 0.1 and mean Spearman’s rank 0.7). In addition, we demonstrate that DRUML predictions of cytarabine sensitivity in clinical leukemia samples are prognostic of patient survival (Log rankp < 0.005). Our results indicate that DRUML accurately ranks anti-cancer drugs by their efficacy across a wide range of pathologies.


  • Cancer Burden Is Controlled by Mural Cell-β3-Integrin Regulated Crosstalk with Tumor Cells

    by Ping-Pui Wong, José M. Muñoz-Félix, Maruan Hijazi, Hyojin Kim, Stephen D. Robinson, Beatriz De Luxán-Delgado, Irene Rodríguez-Hernández, Oscar Maiques, Ya-Ming Meng, Qiong Meng, et al.


  • Open Access

    Prediction of Signed Protein Kinase Regulatory Circuits

    by Brandon M. Invergo, Borgthor Petursson, Nosheen Akhtar, David Bradley, Girolamo Giudice, Maruan Hijazi, Pedro Cutillas, Evangelia Petsalaki, Pedro Beltrao


  • Reconstructing kinase network topologies from phosphoproteomics data reveals cancer-associated rewiring

    by Maruan Hijazi, Ryan Smith, Vinothini Rajeeve, Conrad Bessant, Pedro R. Cutillas

    Understanding how oncogenic mutations rewire regulatory-protein networks is important for rationalizing the mechanisms of oncogenesis and for individualizing anticancer treatments. We report a chemical phosphoproteomics method to elucidate the topology of kinase-signaling networks in mammalian cells. We identified >6,000 protein phosphorylation sites that can be used to infer >1,500 kinase–kinase interactions and devised algorithms that can reconstruct kinase network topologies from these phosphoproteomics data. Application of our methods to primary acute myeloid leukemia and breast cancer tumors quantified the relationship between kinase expression and activity, and enabled the identification of hitherto unknown kinase network topologies associated with drug-resistant phenotypes or specific genetic mutations. Using orthogonal methods we validated that PIK3CA wild-type cells adopt MAPK-dependent circuitries in breast cancer cells and that the kinase TTK is important in acute myeloid leukemia. Our phosphoproteomic signatures of network circuitry can identify kinase topologies associated with both phenotypes and genotypes of cancer cells.